Entrada Therapeutics (TRDA) News Today

$14.58
+0.53 (+3.77%)
(As of 02:43 PM ET)
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Peter S. Kim Purchases 2,276 Shares
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) Director Peter S. Kim acquired 2,276 shares of the business's stock in a transaction dated Wednesday, May 8th. The shares were acquired at an average cost of $14.04 per share, with a total value of $31,955.04. Following the acquisition, the director now directly owns 65,212 shares of the company's stock, valued at approximately $915,576.48. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Peter S. Kim Buys 2,600 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) Director Peter S. Kim acquired 2,600 shares of Entrada Therapeutics stock in a transaction that occurred on Monday, April 8th. The shares were bought at an average price of $13.57 per share, for a total transaction of $35,282.00. Following the transaction, the director now owns 62,936 shares of the company's stock, valued at approximately $854,041.52. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Buys $20,790.00 in Stock
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) Director Peter S. Kim bought 1,512 shares of Entrada Therapeutics stock in a transaction on Thursday, March 28th. The stock was acquired at an average cost of $13.75 per share, for a total transaction of $20,790.00. Following the acquisition, the director now owns 60,336 shares in the company, valued at approximately $829,620. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Buys $42,484.80 in Stock
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) Director Peter S. Kim bought 3,180 shares of Entrada Therapeutics stock in a transaction dated Monday, March 25th. The stock was acquired at an average cost of $13.36 per share, with a total value of $42,484.80. Following the completion of the acquisition, the director now owns 56,074 shares of the company's stock, valued at $749,148.64. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Peter S. Kim Purchases 900 Shares
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) Director Peter S. Kim bought 900 shares of the firm's stock in a transaction dated Tuesday, March 19th. The shares were acquired at an average cost of $12.66 per share, with a total value of $11,394.00. Following the completion of the transaction, the director now owns 47,944 shares of the company's stock, valued at $606,971.04. The purchase was disclosed in a legal filing with the SEC, which is available at this link.
Entrada Therapeutics, Inc. (NASDAQ:TRDA) to Post Q1 2024 Earnings of ($0.40) Per Share, HC Wainwright Forecasts
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Investment analysts at HC Wainwright issued their Q1 2024 earnings per share (EPS) estimates for Entrada Therapeutics in a note issued to investors on Monday, March 18th. HC Wainwright analyst R. Selvaraju forecasts that the company will ea
HC Wainwright Reaffirms "Buy" Rating for Entrada Therapeutics (NASDAQ:TRDA)
HC Wainwright restated a "buy" rating and set a $20.00 price target on shares of Entrada Therapeutics in a report on Monday.
Equities Analysts Offer Predictions for Entrada Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:TRDA)
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Investment analysts at William Blair lowered their Q1 2024 earnings per share estimates for Entrada Therapeutics in a research report issued to clients and investors on Wednesday, March 13th. William Blair analyst M. Minter now forecasts th
Recap: Entrada Therapeutics Q4 Earnings
Entrada Therapeutics, Inc. (NASDAQ:TRDA) CEO Sells $15,990.00 in Stock
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) CEO Dipal Doshi sold 1,000 shares of the business's stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $15.99, for a total value of $15,990.00. Following the transaction, the chief executive officer now owns 244,279 shares in the company, valued at approximately $3,906,021.21. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Entrada Therapeutics (NASDAQ:TRDA) Now Covered by Oppenheimer
Oppenheimer started coverage on Entrada Therapeutics in a research note on Friday. They issued an "outperform" rating and a $22.00 price target on the stock.
Kory James Wentworth Sells 10,206 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) CFO Kory James Wentworth sold 10,206 shares of the company's stock in a transaction on Friday, December 22nd. The shares were sold at an average price of $15.69, for a total transaction of $160,132.14. Following the completion of the sale, the chief financial officer now directly owns 49,571 shares of the company's stock, valued at approximately $777,768.99. The sale was disclosed in a filing with the SEC, which is accessible through this link.
Entrada Therapeutics, Inc. (NASDAQ:TRDA) CEO Dipal Doshi Sells 1,000 Shares
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) CEO Dipal Doshi sold 1,000 shares of the stock in a transaction dated Wednesday, December 20th. The shares were sold at an average price of $15.00, for a total value of $15,000.00. Following the sale, the chief executive officer now owns 245,279 shares of the company's stock, valued at $3,679,185. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
Get Entrada Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TRDA and its competitors with MarketBeat's FREE daily newsletter.

Biden FINISHED On June 13th? (Ad)

Thanks to Biden’s disgraceful leadership we now have sky-high inflation… unchecked immigration… rampant crime… and a “woke mob” hell bent on destroying the America you and I know and love. Biden’s days are numbered.

Click here now to see his shocking evidence.

TRDA Media Mentions By Week

TRDA Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

TRDA
News Sentiment

1.04

0.57

Average
Medical
News Sentiment

TRDA News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

TRDA Articles
This Week

17

1

TRDA Articles
Average Week

Get Entrada Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TRDA and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:TRDA) was last updated on 5/14/2024 by MarketBeat.com Staff

From Our Partners